Back to results
US 6,013,780 AGranted
VEGF.sub.145 expression vectors
AssigneeTechnion Research & Development
InventorsGera Neufeld, Eli Keshet, Israel Vlodavsky, Zoya Poltorak
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTechnion Research & Development
InventorsGera Neufeld, Eli Keshet, Israel Vlodavsky, Zoya Poltorak
Estimating the term…
The present invention relates to a novel VEGF protein product, and nucleic acid encoding the novel protein product, comprising exons 1-6 and 8 of the VEGF gene, and its use thereof in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF.sub.145 has been found to be an active mitogen for vascular endothelial cells and to function as an angiogenic factor in-vivo. VEGF.sub.145 has novel properties compared with previously characterized VEGF species with respect to cellular distribution, susceptibility to oxidative damage, and extra-cellular matrix (ECM) binding ability. The present invention provides methods of treating the cardiovascular system, enhancing endothelialization of diseased vessels, and enhancing drug permeation by providing the novel VEGF protein product. The invention also provides expression vectors, compositions, and kits for use in the methods of the invention.
An isolated polynucleotide comprising exons 1-5, 6a and 8 of the VEGF gene, wherein said polynucleotide does not comprise exon 6b or exon 7 of the VEGF gene.
An expression vector comprising a polynucleotide sequence encoding VEGF.sub.145 operably linked to a regulatory sequence.
Dependencies are inferred from the claim text.